<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Trimethoprim</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00440</strong>&#160; (APRD00103)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to pyrimethamine. The interference with folic acid metabolism may cause a depression of hematopoiesis. It is potentiated by sulfonamides and the trimethoprim-sulfamethoxazole combination is the form most often used. It is sometimes used alone as an antimalarial. Trimethoprim resistance has been reported. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00440/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00440/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00440.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00440.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00440.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00440.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00440.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00440">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Trimethoprim</td><td>German</td><td>INN</td></tr><tr><td>Trim&#233;thoprime</td><td>French</td><td>INN</td></tr><tr><td>Trimethoprimum</td><td>Latin</td><td>INN</td></tr><tr><td>Trimetoprima</td><td>Spanish</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alprim</td><td>Alphapharm</td></tr><tr><td>Catin</td><td>Kojar</td></tr><tr><td>Eumi</td><td>Hwang's</td></tr><tr><td>Inflamnil</td><td>Swiss Pharm</td></tr><tr><td>Lannacher</td><td>Root</td></tr><tr><td>Lariago</td><td>Ipca Laboratories</td></tr><tr><td>Meprim</td><td>Johnson</td></tr><tr><td>Metipine</td><td>Kojar</td></tr><tr><td>Monotrim</td><td>GlaxoSmithKline</td></tr><tr><td>Motrim</td><td>Lannacher</td></tr><tr><td>Primsol</td><td>FSC</td></tr><tr><td>Proloprim</td><td>GlaxoSmithKline</td></tr><tr><td>Trimpex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Triprim</td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Bactrim</td><td>sulfamethoxazole + trimethoprim</td></tr><tr><td>Bethaprim</td><td>sulfamethoxazole + trimethoprim</td></tr><tr><td>Co-trimoxazole</td><td>sulfamethoxazole + trimethoprim</td></tr><tr><td>Cotrim</td><td>sulfamethoxazole + trimethoprim</td></tr><tr><td>Polytrim</td><td>Trimethoprim + Polymyxin B Sulfate</td></tr><tr><td>Septra</td><td>sulfamethoxazole + trimethoprim</td></tr><tr><td>Sulfatrim</td><td>sulfamethoxazole + trimethoprim</td></tr><tr><td>Sulfatrim Pediatric</td><td>sulfamethoxazole + trimethoprim</td></tr><tr><td>Uroplus</td><td>sulfamethoxazole + trimethoprim</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-infective-agents">Anti-Infective Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>738-70-5</td></tr><tr><th>Weight</th><td>Average: 290.3177<br>Monoisotopic: 290.137890462</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>IEDVJHCEMCRBQM-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenol Ethers</td></tr><tr><th>Direct parent</th><td>Anisoles</td></tr><tr><th>Alternative parents</th><td>Alkyl Aryl Ethers; Aminopyrimidines and Derivatives; Primary Aromatic Amines; Polyamines</td></tr><tr><th>Substituents</th><td>alkyl aryl ether; aminopyrimidine; pyrimidine; primary aromatic amine; polyamine; ether; amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the anisoles. These are organic compounds contaiing a methoxybenzene or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea.</td></tr><tr><th>Pharmacodynamics</th><td>Trimethoprim is a pyrimidine analogue that disrupts folate synthesis, an essential part of the thymidine synthesis pathway. Inhibition of the enzyme starves the bacteria of nucleotides necessary for DNA replication.The drug, therefore, exhibits bactericidal activity.</td></tr><tr><th>Mechanism of action</th><td>Trimethoprim binds to dihydrofolate reductase and inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF). THF is an essential precursor in the thymidine synthesis pathway and interference with this pathway inhibits bacterial DNA synthesis. Trimethoprim's affinity for bacterial dihydrofolate reductase is several thousand times greater than its affinity for human dihydrofolate reductase. Sulfamethoxazole inhibits dihydrofolate synthetase (aka dihydropteroate synthetase), an enzyme involved further upstream in the same pathway. Trimethoprim and sulfamethoxazole are commonly used in combination due to their synergistic effects. This drug combination also reduces the development of resistance that is seen when either drug is used alone.</td></tr><tr><th>Absorption</th><td>Readily and almost completely absorbed in the GI tract with peak serum concentrations attained 1-4 hours after oral administration. Widely distributed to tissues and fluids including kidney, lung, seminal fluid, aqueous humour, middle ear fluid, sputum, vaginal secretions, bile, bone and CSF. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>42-46% bound to plasma proteins</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic metabolism to oxide and hydroxylated metabolites.</p></td></tr><tr><th>Route of elimination</th><td>Ten to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine.
After oral administration, 50% to 60% of trimethoprim is excreted in the urine within 24 hours, approximately 80% of this being unmetabolized trimethoprim. Trimethoprim also passes the placental barrier and is excreted in human milk.</td></tr><tr><th>Half life</th><td>8-11 hours in adults with normal renal function</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=4850 (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Gram negative and gram positive bacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.994</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5845</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8631</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8531</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8799</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5732</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8467</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8227
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9369
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9949
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7701 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9394
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8734
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Monarch pharmaceuticals inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Hoffmann la roche inc</li>
<li>Fsc laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aidarex.com">Aidarex Pharmacuticals LLC</a></li>
<li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.alcon.com">Alcon Laboratories</a></li>
<li><a href="http://www.allergan.com">Allergan Inc.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://www.apothecon.nl">Apothecon</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Ascent Pediatrics Inc.</li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li>Avkare Incorporated</li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Carlisle Laboratories Inc.</li>
<li>Casa De Amigos Pharmacy</li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Coupler Enterprises Inc.</li>
<li><a href="http://www.darbydental.com">Darby Dental Supply Co. Inc.</a></li>
<li>Dept Health Central Pharmacy</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.falconpharma.com">Falcon Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.fsclabs.com">FSC Laboratories</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hitechpharm.com">Hi Tech Pharmacal Co. Inc.</a></li>
<li>Innovative Manufacturing and Distribution Services Inc.</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.keltman.com">Keltman Pharmaceuticals Inc.</a></li>
<li><a href="http://www.kingpharm.com">King Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ricaud.com">Laboratoires Docteur Pierre Ricaud</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.larklab.com">Lark Pharmaceuticals Inc.</a></li>
<li>Liberty Pharmaceuticals</li>
<li>Long Island Pharmacal</li>
<li><a href="http://www.lyne.com">Lyne Laboratories Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li>Midland Healthcare LLC</li>
<li>Midland Pharmaceutical LLC</li>
<li><a href="http://www.monarch-pharmacy.co.uk">Monarch Pharmacy</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li>Pacific Pharma Lp</li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patientfirst.com">Patient First Corp.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizerah.com">Pfizer Animal Health</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Association</li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li>Talbert Medical Management Corp.</li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li>Taylor Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li>Vintage Pharmaceuticals Inc.</li>
<li><a href="http://vistapharmaceuticals.com">Vista Pharmaceuticals Inc.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li>Women First Healthcare Inc.</li>
<li>Xactdose Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Bactrim ds tablet</td><td>5.53USD</td><td>tablet</td></tr><tr><td>Bactrim DS 800-160 mg tablet</td><td>3.0USD</td><td>tablet</td></tr><tr><td>Septra DS 800-160 mg tablet</td><td>2.43USD</td><td>tablet</td></tr><tr><td>Septra ds tablet</td><td>2.33USD</td><td>tablet</td></tr><tr><td>Trimethoprim powder</td><td>1.79USD</td><td>g</td></tr><tr><td>Bactrim 400-80 mg tablet</td><td>1.63USD</td><td>tablet</td></tr><tr><td>Septra 80-400 tablet</td><td>1.49USD</td><td>tablet</td></tr><tr><td>Sulfamethoxazole-tmp ds tablet</td><td>1.44USD</td><td>tablet</td></tr><tr><td>Sulfamethoxazole-tmp vial</td><td>0.84USD</td><td>ml</td></tr><tr><td>Trimethoprim 100 mg tablet</td><td>0.7USD</td><td>tablet</td></tr><tr><td>Sulfamethoxazole-Trimethoprim 400-80 mg tablet</td><td>0.69USD</td><td>tablet</td></tr><tr><td>Apo-Trimethoprim 200 mg Tablet</td><td>0.55USD</td><td>tablet</td></tr><tr><td>Primsol 50 mg/5 ml oral soln</td><td>0.39USD</td><td>ml</td></tr><tr><td>Apo-Trimethoprim 100 mg Tablet</td><td>0.27USD</td><td>tablet</td></tr><tr><td>Sulfamethoxazole-tmp ss tablet</td><td>0.17USD</td><td>tablet</td></tr><tr><td>Sulfamethoxazole-Trimethoprim 200-40 mg/5ml Suspension</td><td>0.13USD</td><td>ml</td></tr><tr><td>Sulfatrim 200-40 mg/5ml Suspension</td><td>0.13USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5763449</td><td>1996-08-07</td><td>2016-08-07</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>199-203 &#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>400 mg/L (at 25 &#176;C)</td><td>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</td></tr><tr><td>logP</td><td>0.91</td><td>HANSCH,C ET AL. (1995)</td></tr><tr><td>logS</td><td>-2.86</td><td>ADME Research, USCD</td></tr><tr><td>pKa</td><td>7.12 (at 20 &#176;C)</td><td>PERRIN,DD (1972)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>6.15e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.26</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.28</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.7</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>17.33</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>7.16</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>105.51</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>81.51</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>29.71</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Yasushi Takagishi, Kiichiro Ohsuga, Sadao Ohama, &#8220;Suppository containing sulfamethoxazole/trimethoprim complex and process for preparing the same.&#8221; U.S. Patent US4461765, issued December, 1975.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4461765&amp;tbm=pts" target="_blank">US4461765 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Brumfitt W, Hamilton-Miller JM: Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemother. 1993 Dec;5(6):465-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8195839">Pubmed</a></li>
	<li>Brumfitt W, Hamilton-Miller JM: Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994 Feb;6(1):3-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8071675">Pubmed</a></li>
	<li>Bean DC, Livermore DM, Papa I, Hall LM: Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemother. 2005 Nov;56(5):962-4. Epub 2005 Sep 8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16150859">Pubmed</a></li>
	<li>Felmingham D, Reinert RR, Hirakata Y, Rodloff A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the <span class="caps">PROTEKT</span> surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12239226">Pubmed</a></li>
	<li>Johnson JR, Manges AR, O&#8217;Bryan TT, Riley LW: A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12103291">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00145" target="_blank">D00145 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C01965" target="_blank">C01965 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5578" target="_blank">5578 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507125" target="_blank">46507125 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.5376.html" target="_blank">5376 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18069" target="_blank">18069 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=9731" target="_blank">9731 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL22" target="_blank">CHEMBL22 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000927" target="_blank">DAP000927 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451788" target="_blank">PA451788 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2243116" target="_blank">2243116 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/trimeth.htm" target="_blank">http://www.rxlist.com/cgi/generic2/trimeth.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/trimethoprim.html" target="_blank">http://www.drugs.com/cdi/trimethoprim.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Trimethoprim" target="_blank">Trimethoprim <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>J01EA01<ul class="atc-drug-tree"><li><a href="/atc/J#J">J &#8212; ANTIINFECTIVES FOR SYSTEMIC USE</a></li><li><a href="/atc/J01#J01">J01 &#8212; ANTIBACTERIALS FOR SYSTEMIC USE</a></li><li><a href="/atc/J01E#J01E">J01E &#8212; SULFONAMIDES AND TRIMETHOPRIM</a></li><li><a href="/atc/J01EA#J01EA">J01EA &#8212; Trimethoprim and derivatives</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>08:36.00</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00440.pdf?1265922802">show</a>(98.5 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00440.pdf?1265922741">show</a>(74.3 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01101">Capecitabine</a></td><td>The strong CYP2C9 inhibitor, Capecitabine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Capecitabine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00250">Dapsone</a></td><td>Increased toxicity of both products</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The strong CYP2C9 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Delavirdine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Trimethoprim may significantly reduced the clearance of Dofetilide. Trimethoprim is a cation transport inhibitor and may interfere with renal excretion of Dofetilide. Concomitant use is contraindicated.</td></tr><tr><td><a href="/drugs/DB00322">Floxuridine</a></td><td>The strong CYP2C9 inhibitor, Floxuridine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Floxuridine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>The strong CYP2C9 inhibitor, Fluconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00544">Fluorouracil</a></td><td>The strong CYP2C9 inhibitor, Fluorouracil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluorouracil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00712">Flurbiprofen</a></td><td>The strong CYP2C9 inhibitor, Flurbiprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Flurbiprofen is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Trimethoprim increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>The strong CYP2C9 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Gemfibrozil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>The strong CYP2C9 inhibitor, Ibuprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ibuprofen is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>The strong CYP2C9 inhibitor, Indomethacine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Indomethacine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00650">Leucovorin</a></td><td>The efficacy of Trimethoprim may be reduced by Leucovorin (folinic acid). The antibiotic, Trimethoprim, acts by blocking bacterial folic acid metabolism. Leucovorin may reduce the efficacy of Trimethoprim by providing an alternate source of folic acid. The therapeutic effect of Trimethoprim should be closely monitored.</td></tr><tr><td><a href="/drugs/DB00784">Mefenamic acid</a></td><td>The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>Trimethoprim may increase the adverse/toxic effects of Methotrexate (e.g. bone marrow suppression). Concomitant use should be avoided or closely monitored for Methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>The strong CYP2C9 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Miconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>The strong CYP2C9 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Trimethoprim increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>The strong CYP2C9 inhibitor, Piroxicam, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Piroxicam is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Trimethoprim may reduce the clearance of Procainamide. Alternative treatments should be considered. If Trimethoprim is initiated or the dose is increased, monitor for increased toxicity of Procainamide (e.g. QTc intervals, EKG, serum drug concentrations). If Trimethoprim is discontinued or the dose decreased, monitor for reduced effects of Procainamide.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of trimethoprim</td></tr><tr><td><a href="/drugs/DB06268">Sitaxentan</a></td><td>The strong CYP2C9 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sitaxsentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00359">Sulfadiazine</a></td><td>The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00263">Sulfisoxazole</a></td><td>The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>The strong CYP2C9 inhibitor, Tolbutamide, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Tolbutamide is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The moderate CYP2C8 inhibitor, Trimethoprim, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Trimethoprim is initiated, discontinued to dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.</li>
<li>Take on empty stomach: 1 hour before or 2 hours after meals.</li>
<li>Take with a full glass of water.</li></ul></td></tr></tbody></table>